AIMS: Matrix metalloproteinases (MMPs) have been implicated in the development of hypertension in animal models and humans. Mmp2 deletion did not change Ang II-induced blood pressure (BP) rise. However, whether Mmp2 knockout affects angiotensin (Ang) II-induced vascular injury has not been tested. We sought to determine whether Mmp2 knockout will prevent Ang II-induced vascular injury. METHODS AND RESULTS: A fourteen-day Ang II infusion (1000 ng/kg/min, SC) increased systolic BP, decreased vasodilatory responses to acetylcholine, induced mesenteric artery (MA) hypertrophic remodelling, and enhanced MA stiffness in wild-type (WT) mice. Ang II enhanced aortic media and perivascular reactive oxygen species generation, aortic vascular cell adhesion molecule-1 and monocyte chemotactic protein-1 expression, perivascular monocyte/macrophage and T cell infiltration, and the fraction of spleen activated CD4+CD69+ and CD8+CD69+ T cells, and Ly-6Chi monocytes. Study of intracellular signalling showed that Ang II increased phosphorylation of epidermal growth factor receptor and extracellular-signal-regulated kinase 1/2 in vascular smooth muscle cells isolated from WT mice. All these effects were reduced or prevented by Mmp2 knockout, except for systolic BP elevation. Ang II increased Mmp2 expression in immune cells infiltrating the aorta and perivascular fat. Bone marrow (BM) transplantation experiments revealed that in absence of MMP2 in immune cells, Ang II-induced BP elevation was decreased, and that when MMP2 was deficient in either immune or vascular cells, Ang II-induced endothelial dysfunction was blunted. CONCLUSIONS: Mmp2 knockout impaired Ang II-induced vascular injury but not BP elevation. BM transplantation revealed a role for immune cells in Ang II-induced BP elevation, and for both vascular and immune cell MMP2 in Ang II-induced endothelial dysfunction. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: Matrix metalloproteinases (MMPs) have been implicated in the development of hypertension in animal models and humans. Mmp2 deletion did not change Ang II-induced blood pressure (BP) rise. However, whether Mmp2 knockout affects angiotensin (Ang) II-induced vascular injury has not been tested. We sought to determine whether Mmp2 knockout will prevent Ang II-induced vascular injury. METHODS AND RESULTS: A fourteen-day Ang II infusion (1000 ng/kg/min, SC) increased systolic BP, decreased vasodilatory responses to acetylcholine, induced mesenteric artery (MA) hypertrophic remodelling, and enhanced MA stiffness in wild-type (WT) mice. Ang II enhanced aortic media and perivascular reactive oxygen species generation, aortic vascular cell adhesion molecule-1 and monocyte chemotactic protein-1 expression, perivascular monocyte/macrophage and T cell infiltration, and the fraction of spleen activated CD4+CD69+ and CD8+CD69+ T cells, and Ly-6Chi monocytes. Study of intracellular signalling showed that Ang II increased phosphorylation of epidermal growth factor receptor and extracellular-signal-regulated kinase 1/2 in vascular smooth muscle cells isolated from WT mice. All these effects were reduced or prevented by Mmp2 knockout, except for systolic BP elevation. Ang II increased Mmp2 expression in immune cells infiltrating the aorta and perivascular fat. Bone marrow (BM) transplantation experiments revealed that in absence of MMP2 in immune cells, Ang II-induced BP elevation was decreased, and that when MMP2 was deficient in either immune or vascular cells, Ang II-induced endothelial dysfunction was blunted. CONCLUSIONS: Mmp2 knockout impaired Ang II-induced vascular injury but not BP elevation. BM transplantation revealed a role for immune cells in Ang II-induced BP elevation, and for both vascular and immune cell MMP2 in Ang II-induced endothelial dysfunction. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Tlili Barhoumi; Daniel A Kasal; Melissa W Li; Layla Shbat; Pascal Laurant; Mario F Neves; Pierre Paradis; Ernesto L Schiffrin Journal: Hypertension Date: 2011-01-24 Impact factor: 10.190
Authors: Barbara Schreier; Mirja Hünerberg; Sindy Rabe; Sigrid Mildenberger; Daniel Bethmann; Christian Heise; Maria Sibilia; Stefan Offermanns; Michael Gekle Journal: Clin Sci (Lond) Date: 2015-10-05 Impact factor: 6.124
Authors: Jing Wu; Salim R Thabet; Annet Kirabo; Daniel W Trott; Mohamed A Saleh; Liang Xiao; Meena S Madhur; Wei Chen; David G Harrison Journal: Circ Res Date: 2013-12-17 Impact factor: 17.367
Authors: Guanghong Jia; Javad Habibi; Annayya R Aroor; Michael A Hill; Yan Yang; Adam Whaley-Connell; Frederic Jaisser; James R Sowers Journal: Hypertension Date: 2018-09 Impact factor: 10.190
Authors: Steven J Forrester; George W Booz; Curt D Sigmund; Thomas M Coffman; Tatsuo Kawai; Victor Rizzo; Rosario Scalia; Satoru Eguchi Journal: Physiol Rev Date: 2018-07-01 Impact factor: 37.312
Authors: Marta Czesnikiewicz-Guzik; Ryszard Nosalski; Tomasz P Mikolajczyk; Francesca Vidler; Tomasz Dohnal; Elzbieta Dembowska; Delyth Graham; David G Harrison; Tomasz J Guzik Journal: Br J Pharmacol Date: 2018-12-26 Impact factor: 8.739
Authors: Fabian Emrich; Kiril Penov; Mamoru Arakawa; Nathan Dhablania; Grayson Burdon; Albert J Pedroza; Tiffany K Koyano; Young M Kim; Uwe Raaz; Andrew J Connolly; Cristiana Iosef; Michael P Fischbein Journal: J Cell Mol Med Date: 2019-08-11 Impact factor: 5.310
Authors: Pawel Maga; Tomasz P Mikolajczyk; Lukasz Partyka; Mateusz Siedlinski; Mikolaj Maga; Marek Krzanowski; Krzysztof Malinowski; Kevin Luc; Rafal Nizankowski; Deepak L Bhatt; Tomasz J Guzik Journal: Clin Immunol Date: 2018-06-21 Impact factor: 3.969